Syndax Pharmaceuticals Inc (NASDAQ: SNDX) on Friday, soared 1.79% from the previous trading day, before settling in for the closing price of $12.85. Within the past 52 weeks, SNDX’s price has moved between $12.79 and $25.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1801.91% over the last five years. The company achieved an average annual earnings per share of -21.37%. With a float of $81.08 million, this company’s outstanding shares have now reached $85.57 million.
The firm has a total of 184 workers. Let’s measure their productivity. In terms of profitability, gross margin is -169.78%, operating margin of -1942.5%, and the pretax margin is -1796.46%.
Syndax Pharmaceuticals Inc (SNDX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Syndax Pharmaceuticals Inc is 5.02%, while institutional ownership is 100.30%. The most recent insider transaction that took place on Jun 14 ’24, was worth 25,037. In this transaction Chief Financial Officer of this company bought 1,250 shares at a rate of $20.03, taking the stock ownership to the 52,623 shares.
Syndax Pharmaceuticals Inc (SNDX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.50% during the next five years compared to -0.41% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Syndax Pharmaceuticals Inc (SNDX) is currently performing well based on its current performance indicators. A quick ratio of 6.99 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 71.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.63, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -3.76 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Analysing the last 5-days average volume posted by the [Syndax Pharmaceuticals Inc, SNDX], we can find that recorded value of 3.53 million was better than the volume posted last year of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 5.39%. Additionally, its Average True Range was 0.87.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 3.23%, which indicates a significant decrease from 7.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.19% in the past 14 days, which was lower than the 62.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.35, while its 200-day Moving Average is $20.02. Now, the first resistance to watch is $13.24. This is followed by the second major resistance level at $13.39. The third major resistance level sits at $13.64. If the price goes on to break the first support level at $12.84, it is likely to go to the next support level at $12.59. Now, if the price goes above the second support level, the third support stands at $12.44.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
Market capitalization of the company is 1.14 billion based on 85,358K outstanding shares. Right now, sales total 0 K and income totals -209,360 K. The company made 12,500 K in profit during its latest quarter, and -84,130 K in sales during its previous quarter.
